Associated tags: Vertigo, Tinnitus, RNA, Virus, Hearing loss, Therapy, Allergen, Patient, Allergic rhinitis, Pharmaceutical industry, Vaccine
Locations: NORTH AMERICA, US, BERLIN, SWEDEN, FINLAND, NORWAY, NEW YORK CITY, BOSTON, HAMILTON, BM, SAR, AUSTRALIA, EUROPE, ALTAMIRA, BERMUDA, KRAS, UNITED STATES
Retrieved on:
Wednesday, April 24, 2024
Patient,
Safety,
Pollen,
RNA,
Allergen,
Liver,
Allergy,
NASAR,
Season,
ANCOVA,
Therapy,
MITES,
Pharmaceutical industry HAMILTON, BERMUDA -- April 24, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the publication of the detailed results from the NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR). The peer-reviewed article appeared in Allergy,1 which is published by the European Academy of Allergy and Clinical Immunology and recognizes as one of the highest-ranking journals in the field of allergology. Bentrio (AM-301) is a drug-free and preservative-free nasal spray designed to help protect against airborne allergens such as pollen or house dust mites.
Key Points:
- Bentrio (AM-301) is a drug-free and preservative-free nasal spray designed to help protect against airborne allergens such as pollen or house dust mites.
- The primary efficacy endpoint was the reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS; ANCOVA model).
- Patients and investigators rated the efficacy of treatment as significantly better with Bentrio compared to saline control (both p
- From 2024 onwards, Altamira Medica expects sales to grow significantly, mainly driven by the launch of Bentrio in additional countries.
Retrieved on:
Wednesday, April 10, 2024
FDA,
Drug discovery,
Synovitis,
Cell,
Research,
Vaccine,
IND,
Nanoparticle,
Allergic rhinitis,
DNMT3B,
Dicarboxylic acid,
Inflammation,
Hearing loss,
Osteoarthritis,
Vertigo,
RNA,
Myocardial infarction,
Patent,
CHF,
Messenger,
Betahistine,
Therapy,
Semaphore,
AVS,
Dizziness,
AAV,
Tinnitus,
Heqet,
Rhinitis,
Central nervous system,
Clinical trial,
Small RNA,
Sale,
Cancer,
EDT,
Liver,
Patient,
Rheumatoid arthritis,
Histamine,
Regeneration HAMILTON, BERMUDA -- April 10, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update and reported its full year 2023 financial results.
Key Points:
- "Altamira emerged from the 2023 business year as a stronger and more focused company," commented Thomas Meyer, Altamira Therapeutics' founder, Chairman, and CEO.
- "We keep progressing with our RNA delivery business, concluding recently our second collaboration agreement with another exciting biotech company.
- Altamira expects to make further progress in 2024 with the strategic repositioning by partnering its inner ear therapeutics assets.
- Altamira’s Senior Management will hold an investor call today, Wednesday, April 10, 2024, at 8:30 a.m. EDT to discuss its business update and full-year 2023 results.
Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its Full Year 2023 Financial Results and Business Update Call on Friday, April 10, 2024.
Key Points:
- Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its Full Year 2023 Financial Results and Business Update Call on Friday, April 10, 2024.
- Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts.
Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has entered into a collaboration agreement with Univercells Group (“Univercells”) to evaluate the use of the Company’s proprietary SemaPhore platform for the delivery of mRNA vaccines.
Key Points:
- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has entered into a collaboration agreement with Univercells Group (“Univercells”) to evaluate the use of the Company’s proprietary SemaPhore platform for the delivery of mRNA vaccines.
- Univercells is a global life sciences company creating platforms for developing and manufacturing biologics, including mRNA vaccines and therapeutics, in a simple, scalable and cost-efficient way.
- Should the experiments prove successful, Univercells and Altamira intend to discuss and negotiate a commercial agreement for the development and manufacturing of nanoparticle-based mRNA vaccines using Univercells’ production platform.
- “We are thrilled to initiate this collaboration with Univercells to explore SemaPhore as a delivery vehicle for mRNA vaccines”, commented Covadonga Pañeda, PhD, Altamira’s Chief Operating Officer.
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
Retrieved on:
Wednesday, February 7, 2024
Vivisection,
Peptide,
Cell,
RNA,
Therapy,
Alternative medicine,
Recombinant,
Safety,
FDA,
Dicarboxylic acid,
AVV,
Mouse,
Food,
AAV,
Risk,
Journal,
Tissue,
Cytoplasm,
Melittin,
Vaccine HAMILTON, BERMUDA, Feb. 7, 2024 -- Altamira Therapeutics Ltd. (Nasdaq: CYTO) ("Altamira" or the "Company"), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today the publication of a peer-reviewed article in the Journal of Integrative Medicine titled, "Melittin analog p5RHH enhances recombinant adeno-associated virus transduction efficiency". This work evaluates the use of various peptides to enhance adeno-associated virus (AAV) cell transduction and was conducted by an independent research group.1 Recombinant AAVs are commonly used as carriers to introduce nucleic acids in cells for gene therapy; several AAV-based gene therapy drugs have already been approved by the U.S. Food and Drug Administration (FDA).
Key Points:
- The study sought to find ways of increasing the endosomal release of AAV-based therapeutics by using peptides derived from melittin, a component of bee venom known for its ability to permeabilize biological membranes.
- The research group evaluated 76 melittin derivatives, including p5RHH, the peptide underlying Altamira’s OligoPhore™ / SemaPhore™ nanoparticle platform for RNA delivery.
- The scientists discovered that insertion of p5RHH into the AAV vector (p5RHH-rAAV) not only enhanced cell transduction, but also succeeded in transducing cell lines typically considered resistant to AAVs.
- “Better transduction efficiency means that lower doses of AAVs may be used, which could lower the risk for deleterious immune responses and increase the safety of AAV-based vectors.
Retrieved on:
Wednesday, January 24, 2024
Death,
Neoplasm,
Patient,
Nanoparticle,
Therapy,
Ras GTPase,
RNA,
Small RNA,
Cancer,
NSCLC,
Mutation,
IND,
Lung cancer,
FDA,
Investigational New Drug,
CRC,
Clinical trial,
Colorectal cancer,
Patent,
RAS,
American Cancer Society HAMILTON, BERMUDA, Jan. 24, 2024 -- Altamira Therapeutics Ltd. (Nasdaq: CYTO) ("Altamira" or the "Company"), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has filed a second provisional patent application with the United States Patent and Trade Office (USPTO) to provide broad coverage of different KRAS mutations in human cancer treatment with nanoparticles comprising the Company’s OligoPhore™ platform and a single siRNA sequence, polyKRASmut. The nanoparticles are developed by Altamira as AM-401.
Key Points:
- The second provisional application contains in vitro data confirming the ability of polyKRASmut siRNA to knock down a broad range of KRAS mutations in cancer cell lines.
- Since polyKRASmut was tested against only a limited number of mutations, it may potentially knock down other, yet untested mutations.
- “By combining the polyKRASmut siRNA with our OligoPhore platform we can direct its delivery to the tumor and tackle with one single compound many different KRAS mutations.
- Only recently, the FDA approved the first two treatments for KRAS-driven cancer: sotorasib and adagrasib, two small molecule inhibitors of G12C-mutated KRAS for the treatment of NSCLC.
RNA,
JW Marriott Hotels,
Protein,
Neoplasm,
Tumor microenvironment,
Atherosclerosis,
Messenger,
WNT16,
Aortic aneurysm,
SOD2,
Tissue,
Osteoarthritis,
Therapy,
DNMT3B,
Rheumatoid arthritis,
Inflammation,
Cancer,
Semaphore,
Vaccine HAMILTON, BERMUDA Jan. 8, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today that it will be presenting at the 3rd Annual mRNA-Based Therapeutics Summit, being held January 23-25 at the JW Marriott Hotel, Berlin.
Key Points:
- Altamira’s two flagship programs, AM-401 and AM-411, designed for KRAS-driven cancer and rheumatoid arthritis, serve to demonstrate the technology’s capability to enhance therapeutic efficacy
HAMILTON, BERMUDA Jan. 8, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today that it will be presenting at the 3rd Annual mRNA-Based Therapeutics Summit, being held January 23-25 at the JW Marriott Hotel, Berlin.
- Covadonga Pañeda, Ph.D., the Company's Chief Operating Officer, will give a presentation at the conference titled, "Delivery of therapeutic RNA in inflammation and cancer using peptide-based nanoparticles”.
- “However, even the most powerful mRNA therapeutic is useless if it is not delivered safely and effectively into target cells, which has remained one of the key challenges for non-hepatic targets to date.
- SemaPhore™, Altamira’s peptide-based delivery platform for mRNA, has been successfully tested so far in vivo in models of osteoarthritis (WNT16, DNMT3B), atherosclerosis (p27Kip1), aortic aneurysm (SOD2), and tumor microenvironment (ZBTB46).
Retrieved on:
Friday, December 29, 2023
HAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced that it received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on December 28, 2023, indicating that the Company has regained compliance with the minimum bid price requirement.
Key Points:
- HAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced that it received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on December 28, 2023, indicating that the Company has regained compliance with the minimum bid price requirement.
- On June 26, 2023, the Company was notified by Nasdaq of its failure to maintain a minimum closing bid price of at least $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rule 5550(a)(2) and was given 180 days, or until December 26, 2023, to regain compliance.
- Thanks to its improved equity position, on November 21, 2023 Altamira already regained compliance with the minimum equity requirements for continued listing on Nasdaq.
- Therefore, Altamira is now again in full compliance with the Nasdaq listing requirements for continued listing.
Retrieved on:
Monday, December 11, 2023
RNA,
Allergic rhinitis,
Liver,
IND,
Sale,
Messenger,
Hearing loss,
Small RNA,
International,
Tissue,
Therapy,
Rheumatoid arthritis,
Dizziness,
USD,
International Financial Reporting Standards,
Tinnitus,
Nanoparticle,
Webcast HAMILTON, BERMUDA, Dec. 11, 2023 -- Altamira Therapeutics Ltd. (Nasdaq: CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided an investor and business update highlighting recent activities and milestones achieved following the Company’s partial spin-off of its Bentrio® business and pivot towards becoming a pure-play RNA delivery business.
Key Points:
- Company hosts Investor and Business Update call on December 11 at 8:30 a.m.
- ET
HAMILTON, BERMUDA, Dec. 11, 2023 -- Altamira Therapeutics Ltd. (Nasdaq: CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided an investor and business update highlighting recent activities and milestones achieved following the Company’s partial spin-off of its Bentrio® business and pivot towards becoming a pure-play RNA delivery business.
- Meanwhile, Altamira is also pursuing the partnering of its other legacy assets, which include several development programs in inner ear therapeutics.
- ET to discuss its investor and business update.
